PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
Study Details
Study Description
Brief Summary
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: PD-1 Inhibitor or PD-1 Inhibitor with GVD All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial. |
Drug: PD-1 inhibitor
PD-1 Inhibitor, intravenous drip, d1.
Drug: PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
|
Outcome Measures
Primary Outcome Measures
- Complete remission rate [2 years]
Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.
Secondary Outcome Measures
- Objective Response rate [2 years]
Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.
- Progression Free Survival [5 years]
The time from the start of treatment to the progression of the tumor or death (due to any cause).
- Overall Survival [5 years]
The time from the start of treatment to time of death (due to any cause).
- Duration of Response [5 years]
The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).
- Time to Response (TTR) [2 years]
The time from the start of treatment to the first assessment of complete remission or partial remission.
- Percentage of Participants With Adverse Events [2 years]
Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed classical Hodgkin lymphoma;
-
Refractory to or relapsed after first-line induction therapy; prior radiotherapy is allowed;
-
At least one evaluable lesion according to 2014 Lugano criteria;
-
Life expectancy > 3 months;
-
Eastern Cooperative Oncology Group (ECOG) of 0-1;
-
Able to participate in all required study procedures;
-
Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×109/L); 2) platelet count (> 75×109/L); 3) Hemoglobin (> 80 g/L); 4) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 5) Serum total bilirubin < 1.5 times ULN; 6) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 2.5 times ULN; 7) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) < 1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time). ; 8) Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) were all within the normal range (±10%);
-
There was no evidence that subjects had difficulty breathing at rest, and the measured value of pulse oximetry at rest was more than 92%;
-
Volunteers who signed informed consent.
Exclusion Criteria:
-
Involvement of central nervous system (CNS);
-
Previously received treatment of immune checkpoint inhibitors (eg. PD-1, PD-L1, CTLA-4);
-
Previously received treatment of hematopoietic cell transplantation;
-
Patients with Hemophagocytic syndrome;
-
Patients with active autoimmune diseases requiring systematic treatment in the past two years (hormone replacement therapy is not considered systematic treatment, such as type I diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, adrenocortical dysfunction or pituitary dysfunction requiring only physiological doses of glucocorticoid replacement therapy); Patients with autoimmune diseases who do not require systematic treatment within two years can be enrolled;
-
Requiring treatment with corticosteroids or other immunosuppressive drugs within 14 days of study drug administration [allowing subjects to use local, ocular, intra-articular, intranasal and inhaled glucocorticoid therapy (with very low systemic absorption); and allowing short-term (< 7 days) glucocorticoid prophylaxis (e.g., contrast agent overdose sensitivity) or for the treatment of non-autoimmune diseases (e.g. delayed hypersensitivity caused by contact allergens).
-
Uncontrolled active infection, with the exception of tumor-related B symptom fever;
-
History of human immunodeficiency virus (HIV) infection and/or patients with acquired immunodeficiency syndrome are known;
-
Patients with active hepatitis B or active hepatitis C. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 104 copies/mL) and HCV RNA (no more than the lower limit of the detection method) in the row. Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 104 copies/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the group;
-
Diagnosed with or receiving treatment for malignancy other than lymphoma;
-
Pregnant or breastfeeding women;
-
Other researchers consider it unsuitable for patients to participate in this study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, | Guangzhou | Guangdong | China | 51000 |
2 | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong | China | 510060 |
3 | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou | Guangdong | China | 510060 |
Sponsors and Collaborators
- Sun Yat-sen University
Investigators
- Principal Investigator: Qingqing Cai, MD, Sun Yat-sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B2020-238-01